Researchers examine trends in prescription opioid use for non-cancer pain
Anabolic steroids are chemicals that resemble naturally produced hormones produced in the body. These steroids are widely used by athletes who want to build strong muscles. The anabolic steroids are generally used for certain hormone imbalances, muscle wasting diseases, cancer and endocrine disorders. Anabolic steroids also have virilizing and androgenic properties, which are related to masculine
Full Post: About Anabolic Steroids
A review of more than 4 million insured patients with private coverage and Medicaid, published in the The Journal of Pain showed that rates of opioid use did not differ widely between non-cancer pain conditions but there were higher rates of opioid use among Medicaid patients.
In this study, researchers examined general trends in prescription opioid use in patients covered by HealthCore private insurance and Arkansas Medicaid. They sought to determine if increases in opioids use are limited to particular non-cancer pain (NPC) conditions and how patterns of use differ between NCP conditions and among those with multiple pain conditions.
Trends reported in the study suggest an increased tendency to prescribe long-term opioid therapy, especially for those with multiple pain conditions, which also have been associated with greater psychopathology than single pain conditions. The presence of a comorbid mental disorder may predict opioid use among individuals with chronic pain.
The authors concluded that higher rates of opioid use in the Arkansas Medicaid patients likely reflects the greater disability and disease burden of this population, and added it’s also possible this disadvantaged population has less access to nonopioid rehabilitative therapy for NCP compared with privately insured individuals.
Many women separated from abusive partners still experience high-disability chronic pain after almost two years, according to Canadian researchers writing in The Journal of Pain , the peer review journal of the American Pain Society. Despite ample evidence that chronic pain is a serious problem in women with a history of abuse, little is known
Full Post: Women separated from abusive partners often experience high-disability chronic pain after two years
Interruptions in Medicaid coverage are associated with a higher rate of hospitalization for conditions that can often be treated in an ambulatory care setting, including asthma, diabetes, and hypertension, according to a new study in the Annals of Internal Medicine. The analysis, which examines interrupted Medicaid coverage and hospitalization rates, finds that increased risk for
Full Post: Interruptions in Medicaid coverage associated with a higher rate of hospitalization
The risk of non-AIDS cancer is higher for individuals infected with HIV than for the general population, according to a meta-analysis presented here at the American Association for Cancer Research’s Seventh Annual International Conference on Frontiers in Cancer Prevention Research. Compared with the general population, the risk for non-AIDS cancers was 2.3 times higher for
Full Post: Risk of non-AIDS cancer higher for individuals infected with HIV
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (”IND”) application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest’s proprietary abuse deterrent technology. Najib Babul, PharmD, Chief Executive Officer of
Full Post: TheraQuest’s IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA
People with substance abuse disorders cost Medicaid hundreds of millions of dollars annually in medical care, suggesting that early interventions for substance abuse could not only improve outcomes but also save substantial amounts of money, according to a comprehensive study that examined records of nearly 150,000 people in six states. “Substance abuse probably costs Medicaid
Full Post: The impact of substance use disorders on medical expenditures for Medicaid beneficiaries with behavioral health disorders